Lanean...
DESIGN AND POWERING OF CYSTIC FIBROSIS CLINICAL TRIALS USING RATE OF FEV(1) DECLINE AS AN EFFICACY ENDPOINT
BACKGROUND: Rate of lung function decline (RLFD) (as FEV(1) percent predicted/yr) is a robust measure of CF therapeutic efficacy rarely used as a study endpoint, in part due to uncertainty of sample size requirements. METHODS: Sample size requirements for 1:1 randomizations to detect RLFD treatment...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4079112/ https://ncbi.nlm.nih.gov/pubmed/20646968 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2010.05.004 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|